Intergalactic Therapeutics, an ATP company, is revolutionizing focal gene therapies with a novel non-viral platform comprised of its versatile synthetic and episomal C3 DNA (covalently closed and
circular DNA) molecules; a customized approach to focal therapeutic delivery using its lead delivery
technology, the COMET® pulsed electric field system; and a proprietary cell-free manufacturing
process invented to make gene therapy safer and more accessible for patients. With advanced
programs in ophthalmology as well as expansion areas in additional tissues and diseases, Intergalactic is dedicated to transforming genetic medicine through focal gene therapies.